Using complementary mass spectrometric approaches for the determination of methylprednisolone metabolites in human urine

RATIONALE The metabolism of methylprednisolone is revisited in order to find new metabolites that could be important for distinguishing between different routes of administration. Recently developed liquid chromatography/tandem mass spectrometry (LC/MS/MS) strategies for the detection of corticoster...

Full description

Saved in:
Bibliographic Details
Published in:Rapid communications in mass spectrometry 2012-03, Vol.26 (5), p.541-553
Main Authors: Pozo, Oscar J., Marcos, Josep, Matabosch, Xavier, Ventura, Rosa, Segura, Jordi
Format: Article
Language:English
Subjects:
Administration, Oral
Administration, Topical
Chromatography, Liquid - methods
Gas Chromatography-Mass Spectrometry - methods
Glucocorticoids - administration & dosage
Glucocorticoids - metabolism
Glucocorticoids - urine
Humans
Male
Methylprednisolone - administration & dosage
Methylprednisolone - metabolism
Methylprednisolone - urine
Tandem Mass Spectrometry - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RATIONALE The metabolism of methylprednisolone is revisited in order to find new metabolites that could be important for distinguishing between different routes of administration. Recently developed liquid chromatography/tandem mass spectrometry (LC/MS/MS) strategies for the detection of corticosteroid metabolites have been applied to the study of methylprednisolone metabolism. METHODS The structures of these metabolites were studied using two complementary mass spectrometric techniques: LC/MS/MS in product ion scan mode with electrospray ionization and gas chromatography/mass spectrometry (GC/MS) in full scan mode with electron ionization. Metabolites were also isolated by semipreparative liquid chromatography fractionation. Each fraction was divided into two aliquots; one was studied by LC/MS/MS and the other by GC/MS after methoxyamine‐trimethylsilyl derivatization. RESULTS The combination of all the structural information allowed us to propose a comprehensive picture of methylprednisolone metabolism in humans. Overall, 15 metabolites including five previously unreported compounds have been detected. Specifically, 16β,17α,21‐trihydroxy‐6α‐methylpregna‐1,4‐diene‐3,11,20‐trione, 17α,20β,21‐trihydroxy‐6α‐methylpregna‐1,4‐diene‐3, 11‐dione, 11β,17α,21‐trihydroxy‐6α‐hydroxymethylpregna‐1,4‐diene‐3,20‐dione, 11β,17α,20ξ,21‐tetrahydroxy‐6α‐hydroxymethylpregna‐1,4‐diene‐3‐one, and 17α,21‐dihydroxy‐6α‐hydroxymethylpregna‐1,4‐diene‐3,11,20‐trione are proposed as feasible structures for the novel metabolites. In addition to the expected biotransformations: reduction of the C20 carbonyl, oxidation of the C11 hydroxy group, and further 6β‐hydroxylation, we propose that hydroxylation of the 6α‐methyl group can also take place. CONCLUSIONS New metabolites have been identified in urine samples collected after oral administration of 40 mg of methylprednisolone. All identified metabolites were found in all samples collected up to 36 h after oral administration. However, after topical administration of 5 g of methylprednisolone aceponate, neither the parent compound nor any of the metabolites were detected. Copyright © 2012 John Wiley & Sons, Ltd.
ISSN:0951-4198
1097-0231
DOI:10.1002/rcm.6129